Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
21
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exploring the psychological impact of the 2022 SARS-CoV-2 Omicron variant outbreak in China

      letter
      1 , 1 , 2 , 1 , 2 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 2 , 3 , 4 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 5 , 1 , 3 , 1 , 6 , 7 , 7 , 7 , 1 , 8 , 1 , 2 ,
      General Psychiatry
      BMJ Publishing Group
      anxiety, depression, mental health, COVID-19

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction The impact of the coronavirus disease 2019 (COVID-19) pandemic in 2020 on mental health was substantial in China1 2 and various other countries.3 4 Beyond the direct consequences of COVID-19, the pandemic created an environment in which many determinants of mental health were affected. Issues associated with the pandemic, such as loss of livelihood, limited access to medical services, reduced social interactions, and economic downturn, could potentially have adverse effects on the population’s mental well-being.5 In November 2021, the World Health Organization (WHO) designated the new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), variant B.1.1.529, as a variant of concern and named it Omicron; its rapid mutation and spread raised a new global health concern.6 The first wave of the Omicron outbreak in mainland China started in Shanghai in late February 2022.5 Subsequently, it led to a few small eruptions in several cities in China,7 despite multifaceted public health interventions. After evaluating the pathogenicity, immunity evasion, transmission of the virus, and possible consequences of the Omicron wave, the State Council of China lifted the strict virus control measures on December 7, 2022.8 The official release from attempting to control the epidemic rapidly ushered in the first widespread wave of Omicron, peaking within a month. The number of infected people across the country increased explosively.9 10 The pandemic’s evident impact on netizens’ health emphasised the need for up-to-date information on the prevalence of infectious symptoms and mental health effects. Unfortunately, the threat of future pandemics exists.11 Investigating the impact of epidemics, such as Omicron, and incorporating the findings in ways that inform health system responses has never been more urgent. However, there are few large-scale studies containing significant evidence to explain the effects of recent pandemics in large, widespread regions such as China. In January 2023, this study investigated the prevalence of the infectious illness and mental health-related symptoms among the general Chinese population during the nationwide Omicron outburst using a self-reported, anonymous online survey. It calculated population-attributable fractions (PAF) of the Omicron wave of the COVID-19 pandemic for common mental health-related adverse effects. We hypothesised that the prevalence rates of infection, anxiety, depression, acute stress and insomnia symptoms in China would increase dramatically. However, we also contended that the potential for preventing mental disorders during pandemics in China was considerable. Methods Study design and participants Figure 1 shows the flowchart of study participants. We used market research sampling to conduct a cross-sectional anonymous online survey. An invitation sought online adult volunteers from throughout China to participate in the study to evaluate the effects of the recent nationwide Omicron variant spread on respondents’ daily lives and mental health status. A quick response code linking the online questionnaire was released to the public accounts of WeChat and QQ—two of China’s largest online social platforms—during January 2–9, 2023. Necessary explanations and guidance about the form completion and survey process (ie, information about confidentiality) were provided before the survey began. The inclusion criteria were (1) age >16 years, (2) Chinese resident living in mainland China and (3) willingness to complete the survey. The exclusion criterion was a history of psychotic disorders diagnosed at a medical institution. Written informed consent was obtained online before the respondents completed the questionnaire. Figure 1 The flowchart of study participants. Self-measurement and procedures Participants were asked to complete a structured questionnaire with six sections: (1) sociodemographic characteristics; (2) self-reported signs and symptoms of the COVID-19 infection and current clinical status; (3) worries about the infection, re-infection and the sequelae of the illness; (4) the impact of the pandemic on quality of life, accessibility to medical services and social interactions; (5) an evaluation of common mental health-related symptoms—namely anxiety, depression and stress—in the past 2 weeks as measured by the Chinese versions of Generalised Anxiety Disorder-7 Scale (GAD-7),12 Patient Health Questionnaire-9 (PHQ-9)13 and Perceived Stress Scale-10 (PSS-10),14 respectively and (6) an assessment of sleep problems as evaluated by the Pittsburgh Sleep Quality Index (PSQI).15 The survey required approximately 10 minutes to complete. Moderate-to-severe anxiety, depression, acute stress and insomnia were defined by a GAD-7 score ≥10, a PHQ-9 score ≥10, a PSS-10 score ≥21 and a PSQI score ≥9, respectively. Notably, the instruments used in this survey offer clinicians self-administered screening and diagnostic tools for mental health disorders and have been tested in clinical settings with many comparable prepandemic estimates.13 Detailed information about these scales is provided in the online supplemental material. 10.1136/gpsych-2023-101088.supp1 Supplementary data Statistical analysis Statistical analyses were performed using SPSS statistical software V.26 (SPSS, IBM, Armonk, New York, USA). The distribution of participant characteristics was described. Chi-square tests were used to assess the prevalence of anxiety, depression, acute stress and insomnia in the total sample, along with demographic characteristics and pandemic-related factors. Furthermore, logistic regression models were used to examine the possible correlates of the four types of mental health-related symptoms. The odds ratio (OR) and 95% confidence interval (CI) were determined. Additionally, we used OR estimates from this survey data to calculate PAF for six Omicron wave-related factors. PAF calculates the proportion of psychological symptoms that would not occur in a population if each risk factor was to be eliminated. The weighted PAF indicates the contribution of each pandemic factor to the overall PAF after adjusting for communality (ie, overlap between risk factors). We used these values to calculate the overall weighted PAF for the four types of mental health-related symptoms.16 The significance level was set at p<0.05. We used the Bonferroni method to correct the p values for analyses of more than one primary outcome. Results Characteristics of participants Overall, 95 009 individuals visited the survey webpage by WeChat and QQ platforms during January 2–9 2023, and 69 926 individuals provided informed consent and proceeded with the survey, with a response rate of 73.6%. We excluded 38 670 individuals in the analysis phase, among whom 28 868 had missing data; 3175 were from Hong Kong, Taiwan, Macao or overseas; 4992 spent less than 2 minutes or more than 15 minutes answering the questionnaire and 1635 duplicated answers or used the same IP addresses (figure 1). The study finally included 31 256 eligible participants from all over China, including the 4 municipalities, 22 provinces, and 5 autonomous regions of mainland China: 28 940 (92.6%) were aged 19–50 years, 16 858 (53.9%) were female, and 25 384 (81.2%) had college education or above. Of the total, 8192 (26.2%) were worried about a viral infection or re-infection, and 9732 (31.1%) were worried about the COVID-19 sequelae. Additionally, 9562 (30.6%), 9622 (30.8%) and 9979 (31.9%) perceived the pandemic had greatly impacted their quality of life, medical accessibility and social interactions, respectively. Moreover, 24 893 (79.6%) participants self-reported having been infected by the virus, while 6363 (20.4%) reported having had no infection (online supplemental table 1). We categorised the 16 typical self-reported infection symptoms into five types according to organs and systems, and supplementary table 2 shows the rates of them (online supplemental file 2). The prevalence of moderate-to-severe symptoms for the four mental health conditions in the sample was 25.9% for anxiety, 36.9% for depression, 13.6% for acute stress and 56.6% for insomnia (online supplemental table 3). 10.1136/gpsych-2023-101088.supp2 Supplementary data Impact of the related factors of the Omicron wave of COVID-19 on anxiety, depression, acute stress and insomnia symptoms We estimated the PAF of six factors—actively infected with the Omicron variant of the SARS-CoV-2 virus, worried about becoming infected, re-infection and the sequelae of the infection, the impact on quality of life, accessibility to medical services, and social interactions—related to the Omicron wave of the COVID-19 pandemic for the four mental health-related symptoms based on the ORs listed in online supplemental table 4. The proportion of anxiety, depression, acute stress, and insomnia symptoms that were theoretically attributed to the six pandemic factors—overall weighted PAF—was 21.9% (95% CI: 21.4% to 22.4%), 19.2% (95% CI: 18.8% to 19.6%), 18.1% (95% CI: 17.7% to 18.5%) and 10.7% (95% CI: 10.4% to 11.0%), respectively (figure 2A–D, table 1 and online supplemental table 5). Surprisingly and in contrast to other factors, having an active infection was not a risk factor with a weighted PAF of −10.8% (95% CI: −11.2% to −10.4%) for anxiety; −4.1% (95% CI: −4.3% to −3.9%) for depression; −2.8% (95% CI: −3.0% to −2.6%) for acute stress, and −0.5% (95% CI: −0.6% to −0.4%) for insomnia (table 1 and online supplemental table 5). Therefore, we did a subanalysis to assess the ORs by clinical stage and frequency of infection (online supplemental table 6), showing that the participants who had recovered from the illness were less likely to have continuous anxiety (OR: 0.92, 95% CI: 0.85 to 0.98, p=0.01) or insomnia (OR: 0.94, 95% CI: 0.89 to 1.00, p=0.04) than those who were actively infected. Furthermore, people with a second infection were less likely to have symptoms of anxiety (OR: 0.88, 95% CI: 0.79 to 0.98, p=0.02), depression (OR: 0.79, 95% CI: 0.72 to 0.88, p=0.001) or insomnia (OR: 0.66, 95% CI: 0.60 to 0.73, p<0.001) than those with a first infection. Lastly, the correlation between the frequency and prevalence of acute stress was not statistically significant. Table 1 PAF for the Omicron wave of COVID-19-related factors for symptoms of anxiety, depression, acute stress and insomnia (n=31 256)* Risk factors Communality (%) Anxiety† Depression‡ Acute stress§ Insomnia¶ WPAF (%)(95% CI) WPAF (%)(95% CI) WPAF (%)(95% CI) WPAF (%)(95% CI) Actively infected with the Omicron variant of the SARS-CoV-2 virus 99.9 −10.8(−11.2 to -10.4) −4.1(−4.3 to −3.9) −2.8(−3.0 to −2.6) −0.5(−0.6 to −0.4) Worried about becoming infected or re-infection 78.2 3.3(3.1 to 3.5) 2.1(1.9 to 2.3) 2.2(2.0 to 2.4) 1.3(1.2 to 1.4) Worried about the sequelae of the infection 74.1 5.4(5.1 to 5.7) 4.3(4.1 to 4.5) 4.2(4.0 to 4.4) 2.0(1.8 to 2.2) Impacted life quality 99.5 6.8(6.5 to 7.1) 4.6(4.4 to 4.8) 4.3(4.1 to 4.5) 2.2(2.0 to 2.4) Impacted accessibility to medical services 68.8 8.2(7.9 to 8.5) 6.0(5.7 to 6.3) 4.6(4.4 to 4.8) 3.1(2.9 to 3.3) Impacted social interactions 75.3 9.0(8.7 to 9.3) 6.1(5.8 to 6.4) 5.6(5.3 to 5.9) 2.6(2.4 to 2.8) Overall weighted PAF 21.9(21.4 to 22.4) 19.2(18.8 to 19.6) 18.1(17.7 to 18.5) 10.7(10.4 to 11.0) *The PAF value for each risk factor was calculated based on the prevalence and the strength of its association (OR) with the four mental disorders. WPAF is the contribution of each pandemic factor to the overall PAF when adjusted for communality (see online supplemental material for specific calculation methods). †Scores of 10–21 for the Generalised Anxiety Disorder-7 were defined as anxiety. ‡Scores of 10–27 for the Patient Health Questionnaire-9 were defined as depression. §Scores of 21–40 for the Perceived Stress Scale-10 were defined as acute stress. ¶Scores of 9–21 on the Pittsburgh Sleep Quality Index were defined as insomnia. CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio; PAF, population-attributable fractions; WPAF, weighted population-attributable fractions. Figure 2 The PAF for the impact of Omicron wave of the COVID-19-related factors on mental health in China. PAF calculates the proportion of psychological symptoms that would not occur in a population if each risk factor was to be eliminated. The weighted PAF indicates the contribution of each pandemic factor to the overall PAF after adjusting for communality (ie, overlap between risk factors). PAF, population-attributable fractions. Discussion Main findings In this nationwide survey, the prevalence of moderate-to-severe symptoms of anxiety, depression, acute stress and insomnia was 25.9%, 36.9%, 13.6%, and 56.6%, respectively. Notably, the prevalence of symptoms of anxiety and depression during the Omicron wave was twofold higher than during the first wave of the COVID-19 pandemic1 and eightfold higher than before the COVID-19 pandemic in China.17 Additionally, the prevalence of moderate-to-severe insomnia was ninefold higher than in the first wave of the COVID-19 pandemic.1 However, the prevalence of acute stress related to COVID-19 was lower than in a previous online survey in China1; however, the screening tools used in the two surveys differed. In our study, 21.9% of anxiety, 19.2% of depression, 18.1% of acute stress and 10.7% of insomnia were theoretically attributed to epidemic-related factors. Among individual epidemic-related factors, the PAF order from greatest to smallest was as follows: perceived impact on social interactions>impact on accessibility to medical services>impact on quality of life>worries about the sequelae>worries about active COVID-19-related infection or re-infection. Notably, being actively infected contributed to a reduced risk of adverse mental health-related outcomes, differing from previous survey findings in China17 but consistent with other studies.18 Recovery from an infection of the virus and possibly a re-infection may have contributed to the reduced risk. Together, these findings suggest a profile of the population’s response to the wide-ranging upheavals experienced during the Omicron outbreak and provide evidence for the increased prevalence of adverse mental health-related outcomes. These results, along with other studies, can inform population-level mental health management and intervention strategies when responding to epidemic outbreaks. Before the COVID-19 outbreak, depressive and anxiety disorders were the leading contributors to the global mental health burden.19 In China, the 12-month prevalence rates of depressive and anxiety disorders in the general population were 3.6% and 5.0%, respectively.17 The COVID-19 pandemic in 2020 substantially increased the prevalence and burden of major mood disorders.20 The prevalence of anxiety, depression, acute stress and insomnia in China increased dramatically during the first wave of the COVID-19 pandemic.1 21 However, China’s first wave of the COVID-19 pandemic was mainly limited to Hubei Province, as aggressive non-pharmaceutical public health interventions abated it quickly in early 2020.22 Unlike that outbreak, the Omicron wave at the end of 2022 rapidly spread to the entire country, disrupting many aspects of life for the entire population within a short period of one month. This was unlike other countries and regions where peaks of the SARS-CoV-2 Omicron wave ranged from several months to years.23 24 Therefore, the conditions in which the Chinese population was exposed to the Omicron variant differed from those in other countries and from the early pandemic conditions in China in early 2020. Our timely study during this wave suggests that the impact of the epidemic on the prevalence of major mental disorder symptoms was more substantial during the 2022–2023 outbreak than in 2020. We systematically demonstrated the risk of mental health consequences associated with pandemic factors and estimated the proportion of mental health outcomes attributable to six pandemic-related factors in China. The impact people perceived on their social life, accessibility to medical services, quality of daily life, and worries about the sequelae, infection or re-infection were the top factors that contributed to mental health-related symptoms. Partially consistent with a previous report,25 these factors highlight the potential priorities for preventing mental disorders in pandemics. To date, no published research has estimated the PAF for mental health-related symptoms using epidemic factors. However, using different measures, the COVID-19 Mental Disorders Collaborators26 estimated that the global prevalence of depression and anxiety increased by 27.6% and 25.6%, respectively, in the general population during the COVID-19 pandemic. Unlike previous studies that reported an association between self-reporting of COVID-19 and mental health deterioration27 and sleep quality,28 our study found that self-reported infection did not contribute to adverse mental health-related symptoms. We further found that participants who recovered from the illness were less likely to have symptoms of anxiety and insomnia than those who were actively ill. Additionally, participants who had re-infections were less likely to suffer from anxiety, depression and insomnia than those with a first-time infection. This finding provides new evidence that, for most people, adverse life events result in initial short-term increases in symptoms of mental distress, followed by recovery. Moreover, this pattern is consistent with the results of large-scale studies on COVID-19.29 Furthermore, the outbreak of the Omicron variant in China in December 2022 differed from that in other countries and regions. Most people in China were infected over a short period of time; however, in our study, their symptoms were mild to moderate, as 13.2% were asymptomatic, 81.6% had systemic symptoms, 62.6% had respiratory symptoms and 16.5% had gastrointestinal symptoms; only 7.2% of the participants experienced life-threatening shortness of breath. At the time of writing this article, the COVID-19 pandemic in China has declined drastically, according to a report from the National Health Commission of the People’s Republic of China.30 Limitations First, given the nature of the online survey, most participants were young and highly educated, limiting the sample’s representativeness, especially that of older adults. Second, we relied on self-rating scales rather than clinical diagnoses to estimate the prevalence of common mental health-related symptoms. The prevalence estimates of common mental health-related outcomes assessed using screening tools are considerably higher than those from diagnostic interviews. Third, given the nature of this cross-sectional study, causal relationships between mental health-related symptoms and risk factors cannot be established. Implications In conclusion, self-reported mental health-related symptoms increased dramatically during the late 2022 to early 2023 Omicron wave in China. Worries and perceived impact, rather than the actual infection, contributed greatly to this increase. To inform ongoing work in the field, timely, high-quality surveys during epidemic outbreaks in China are required.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          A Global Measure of Perceived Stress

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science

            Summary The coronavirus disease 2019 (COVID-19) pandemic is having a profound effect on all aspects of society, including mental health and physical health. We explore the psychological, social, and neuroscientific effects of COVID-19 and set out the immediate priorities and longer-term strategies for mental health science research. These priorities were informed by surveys of the public and an expert panel convened by the UK Academy of Medical Sciences and the mental health research charity, MQ: Transforming Mental Health, in the first weeks of the pandemic in the UK in March, 2020. We urge UK research funding agencies to work with researchers, people with lived experience, and others to establish a high level coordination group to ensure that these research priorities are addressed, and to allow new ones to be identified over time. The need to maintain high-quality research standards is imperative. International collaboration and a global perspective will be beneficial. An immediate priority is collecting high-quality data on the mental health effects of the COVID-19 pandemic across the whole population and vulnerable groups, and on brain function, cognition, and mental health of patients with COVID-19. There is an urgent need for research to address how mental health consequences for vulnerable groups can be mitigated under pandemic conditions, and on the impact of repeated media consumption and health messaging around COVID-19. Discovery, evaluation, and refinement of mechanistically driven interventions to address the psychological, social, and neuroscientific aspects of the pandemic are required. Rising to this challenge will require integration across disciplines and sectors, and should be done together with people with lived experience. New funding will be required to meet these priorities, and it can be efficiently leveraged by the UK's world-leading infrastructure. This Position Paper provides a strategy that may be both adapted for, and integrated with, research efforts in other countries.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

              (2021)
              Background Before 2020, mental disorders were leading causes of the global health-related burden, with depressive and anxiety disorders being leading contributors to this burden. The emergence of the COVID-19 pandemic has created an environment where many determinants of poor mental health are exacerbated. The need for up-to-date information on the mental health impacts of COVID-19 in a way that informs health system responses is imperative. In this study, we aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020. Methods We conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021. We searched PubMed, Google Scholar, preprint servers, grey literature sources, and consulted experts. Eligible studies reported prevalence of depressive or anxiety disorders that were representative of the general population during the COVID-19 pandemic and had a pre-pandemic baseline. We used the assembled data in a meta-regression to estimate change in the prevalence of major depressive disorder and anxiety disorders between pre-pandemic and mid-pandemic (using periods as defined by each study) via COVID-19 impact indicators (human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate). We then used this model to estimate the change from pre-pandemic prevalence (estimated using Disease Modelling Meta-Regression version 2.1 [known as DisMod-MR 2.1]) by age, sex, and location. We used final prevalence estimates and disability weights to estimate years lived with disability and disability-adjusted life-years (DALYs) for major depressive disorder and anxiety disorders. Findings We identified 5683 unique data sources, of which 48 met inclusion criteria (46 studies met criteria for major depressive disorder and 27 for anxiety disorders). Two COVID-19 impact indicators, specifically daily SARS-CoV-2 infection rates and reductions in human mobility, were associated with increased prevalence of major depressive disorder (regression coefficient [ B ] 0·9 [95% uncertainty interval 0·1 to 1·8; p=0·029] for human mobility, 18·1 [7·9 to 28·3; p=0·0005] for daily SARS-CoV-2 infection) and anxiety disorders (0·9 [0·1 to 1·7; p=0·022] and 13·8 [10·7 to 17·0; p<0·0001]. Females were affected more by the pandemic than males ( B 0·1 [0·1 to 0·2; p=0·0001] for major depressive disorder, 0·1 [0·1 to 0·2; p=0·0001] for anxiety disorders) and younger age groups were more affected than older age groups (−0·007 [–0·009 to −0·006; p=0·0001] for major depressive disorder, −0·003 [–0·005 to −0·002; p=0·0001] for anxiety disorders). We estimated that the locations hit hardest by the pandemic in 2020, as measured with decreased human mobility and daily SARS-CoV-2 infection rate, had the greatest increases in prevalence of major depressive disorder and anxiety disorders. We estimated an additional 53·2 million (44·8 to 62·9) cases of major depressive disorder globally (an increase of 27·6% [25·1 to 30·3]) due to the COVID-19 pandemic, such that the total prevalence was 3152·9 cases (2722·5 to 3654·5) per 100 000 population. We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6) per 100 000 population. Altogether, major depressive disorder caused 49·4 million (33·6 to 68·7) DALYs and anxiety disorders caused 44·5 million (30·2 to 62·5) DALYs globally in 2020. Interpretation This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option. Funding Queensland Health, National Health and Medical Research Council, and the Bill and Melinda Gates Foundation.
                Bookmark

                Author and article information

                Journal
                Gen Psychiatr
                Gen Psychiatr
                gpsych
                gpsych
                General Psychiatry
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2517-729X
                2023
                6 December 2023
                : 36
                : 6
                : e101088
                Affiliations
                [1 ]departmentInstitute of Brain Science and Advanced Technology , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [2 ]departmentDepartment of Neurology, Geriatric Hospital Affiliated to Wuhan University of Science and Technology , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [3 ]departmentDepartment of Neurology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [4 ]departmentInstitute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [5 ]departmentDepartment of Anesthesiology , Ringgold_12390Zhongnan Hospital, Wuhan University , Wuhan, Hubei, China
                [6 ]departmentDepartment of Neurology, Wuchang Hospital affiliated to Wuhan University of Science and Technology , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [7 ]departmentDepartment of neurology, Asian Heart Hospital , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                [8 ]departmentSchool of Public Health , Ringgold_47900Wuhan University of Science and Technology , Wuhan, Hubei, China
                Author notes
                [Correspondence to ] Dr Yan Zeng; zengyan68@ 123456wust.edu.cn

                GH, GC, FH and CL are joint first authors.

                Author information
                http://orcid.org/0000-0002-5119-5448
                Article
                gpsych-2023-101088
                10.1136/gpsych-2023-101088
                10711810
                38089413
                d01592a7-8735-431f-8c96-6e6f1c78445a
                © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 21 April 2023
                : 19 October 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100012166, National Key Research and Development Program of China;
                Award ID: 2020YFC2006000
                Categories
                Letter
                1506
                2474
                Custom metadata
                unlocked

                anxiety,depression,mental health,covid-19
                anxiety, depression, mental health, covid-19

                Comments

                Comment on this article